Drug Profile
TTC 352
Alternative Names: TTC-352Latest Information Update: 03 Mar 2023
Price :
$50
*
At a glance
- Originator University of Illinois at Chicago
- Developer TTC Oncology
- Class Antineoplastics; Small molecules; Thiophenes
- Mechanism of Action Estrogen receptor alpha agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Breast cancer